| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Scoping commencing |
| Process | STA Standard |
| ID number | 4041 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
| External Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
| Companies sponsors | Apellis (pegcetacoplan) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Macular Society |
| Professional groups | Royal College of Ophthalmologists |
| Royal College of Physicians | |
| Associated public health groups | None |
| Comparator companies | None |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 April 2024 | Following a regulatory update from the company, the timelines for this appraisal are to be confirmed. |
| 16 August 2023 | Invitation to participate |
| 19 July 2023 | Stakeholder workshop |
| 26 May 2023 - 26 June 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4041 |
| 26 May 2023 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual